Trial Profile
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs CEP 11981 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 24 Jun 2023 Status changed from active, no longer recruiting to completed.
- 30 Aug 2022 Planned End Date changed from 31 Oct 2022 to 18 Jun 2023.
- 30 Aug 2022 Planned primary completion date changed from 31 Oct 2022 to 15 May 2023.